Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Anders Sönnerborg, Stéphane De Wit et al.|Clinical Infectious Diseases|2023Cited by 23
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, H Appoyer, Lene Ryom et al.|Clinical Infectious Diseases|2020Cited by 22
Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic ReviewVani Vannappagari, Michael Aboud, Leigh Ragone et al.|Antiviral Therapy|2018Cited by 18
A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World SettingsCassidy Henegar, Vani Vannappagari, Emilio Letang et al.|Viruses|2023Cited by 13
Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA studyAnnegret Pelchen–Matthews, Jakob Friis Larsen, Leah Shepherd et al.|HIV Research & Clinical Practice|2021Cited by 13